With its orally bioavailable inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1), Glenmark Pharmaceuticals Ltd. is advancing a novel therapeutic target in pain management, an area that has seen limited progress in recent times. However, pain is not a core focus for the Indian company.
The Mumbai-based firm has received the go-ahead from India’s Directorate General of Health Services, Central Drugs Standard Control Organization (CDSCO)...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
